100380191.pdf

```markdown
Evaluation Warning: The version can be used only for evaluation purpose...
Equity Research

Pharmaceuticals, Denmark

# Novo Nordisk

**Focus turns to weekly Wegovy prescriptions**

*   Solid Q4, upbeat outlook, but muted revisions
*   Focus turns to weekly US Wegovy prescription data
*   HOLD/MARKET PERFORM, target price up to DKK1,150 (1,100)

**Marginal revisions**

Following the Q4 report, we introduce revised forecasts for 2023 and beyond. Compared to Novo's guidance in local currencies of 13-19% sales and EBIT growth in 2023, we end up at 15% and 14%, respectively. For 2023e-2025e, we make 1-3% upward EPS revisions.

**Wegovy the swing factor in outlook**

The outlook range was broader than normal, and Novo stated that the high and low end of the range (a delta of USD 1.5bn in 2023e revenue) is mainly linked to alternative scenarios for Wegovy, the anti-obesity agent, relaunch in the US. During Q4, Wegovy beat company-compiled consensus by DKK 1bn, which equalled the amount Novo defined as 'wholesale pipeline filling'. Our revised 2023 revenue forecast for Wegovy is 2% below consensus, most likely as we use a lower USD/DKK conversion than consensus uses.

**Wegovy relaunch with weekly prescriptions in focus**

Now focus turns to weekly US Wegovy prescription data. The shares strengthened after Friday's 50,000+ reported prescriptions during the week: up 21% w-o-w. However, Novo has flagged that due to warehousing of patients ahead of the relaunch of Wegovy, it is difficult to make too much of the weekly data until late Q1, due to the stocking effects of patients. In mid-2023, the CV outcome trial SELECT will read out, which will also be crucial for the long-term potential of Wegovy.

Mattias Häggblom, +46 8 701 1256, msha03@handelsbanken.se

Suzanna Queckbörner, +46 8 701 1349, suqe01@handelsbanken.se

Company page on Handelsbanken's REON

Estimate changes

Short-term recommendation (3 months)

S
Sell
H
HOLD
B
Buy

Long-term recommendation (3 years)

UMO
Underperform MARKET PERFORM Outperform

Results Comment Q4 2022 February 06, 2023, 19:09 CET

Share price (DKK) Feb 06, 19:01 CET 958.0
Market cap (EURm) 293,412
Market cap (DKKm) 2,184,240
No of shares (m) 2,280
Freefloat (%) 92.3
Avg daily volume (000) 1,785
Avg daily value (EURm) 226
Bloomberg NOVOB DC
Reuters NOVOb.CO
Next event 04/05/2023: Q1 report
Web address: Link to company website
IR web address: Link to IR web site

3-year target return

Target price incl. div (DKK) 1,150
Expected total return (%) 20.0
Of which expected total dividendyield (%) 8.8

2023-02-06

|                    | Votes (%) | Capital (%) |
| ------------------ | --------- | ----------- |
| Novo Holdings A/S  | 76.9      | 28.1        |
| Capital Research & Management Co. | 0.92    |  2.9      |
| The Vanguard Group, Inc.     | 0.61  |    1.9      |
| Norges Bank Investment Management  | 0.56    |  1.7      |
| Novo Nordisk A/S   | 0.44      | 1.4         |

Total number of shares(m) 2,280
Free float (%) 74.0

| DKKm             | 2020    | 2021    | 2022    | 2023e   | 2024e   | 2025e   |
| ---------------- | ------- | ------- | ------- | ------- | ------- | ------- |
| Sales            | 126,946 | 140,800 | 176,954 | 199,753 | 226,936 | 257,572 |
| Sales growth (%) | 4.0     | 10.9    | 25.7    | 12.9    | 13.6    | 13.5    |
| Gross margin (%) | 83.5     | 83.2    | 83.9    | 85.0    | 85.1    | 85.4    |
| EBIT adj         | 54,126  | 58,644  | 74,809  | 83,528  | 94,371  | 109,743 |
| margin (%)       | 42.6    | 41.7    | 42.3    | 41.8    | 41.6    | 42.6    |
| EBT              | 53,130  | 59,080  | 69,062  | 85,928  | 93,846  | 109,218 |
| EPS rep (DKK)    | 18.0    | 20.7    | 24.4    | 30.3    | 33.6    | 39.8    |
| EPS adj (DKK)    | 18.1    | 20.7    | 24.4    | 30.3    | 33.6    | 39.8    |
| Y-o-y growth (%) | 11      | 15      | 18      | 24      | 11      | 18      |
| EPS adj revisions (%)| n.m     | n.m    | n.m    | 3    | 1    | 3    |
| P/E adj (x)    | 23.6    | 35.4    | 38.4    | 31.6    | 28.5    | 24.1    |
| P/BV (X)     | 15.8    | 24.1    | 25.7    | 21.9    | 19.3    | 16.2    |
| ROE adj (%)    | 69.7    | 71.2    | 72.0    | 75.3    | 71.9    | 73.1    |
| EV/EBIT (x)   | 18.4    | 29.1    | 28.6    | 25.5    | 22.3    | 18.8    |
| EV/sales (x)  | 7.9    | 12.1    | 12.1    | 10.7    | 9.3    | 8.0    |
| FCF adj yield (%)    | 4.6    | 2.9    | 3.1    | 2.6    | 2.8    | 3.4    |
| Tot DPS (DKK)    | 9.1    | 10.4    | 12.4    | 15.3    | 16.9    | 20.0    |
| Totdivyield (%)    | 2.1    | 1.4    | 1.3    | 1.6    | 1.8    | 2.1    |
| Net debt/equity (%)    | -8.0    | 10.7    | -1.2    | -2.0    | 1.9    | -0.21    |

Source: Handelsbanken Capital Markets

Absolute and relative performance

![](./dummy_image.png)

Share performance (%) -1m -3m -12m

Absolute: -0.98 13.8 48.2

Absolute EUR: -1.1 13.8 48.2

Relative (OMXCPI (DK)): -3.0 -0.66 30.8

52w range (DKK): 968.3/642.9

Source: FactSet

For full disclaimer and definitions, please refer to the end of this report.

Handelsbanken Capital Markets
```
```markdown
Evaluation Warning: The version can be used only for evaluation purpose...
Results Comment, Novo Nordisk, February 6, 2023

# Supporting tables and charts

**Table 1: Deviation table (DKKm)**
NOVO NORDISK

|                          | Q4 2022 Actual | Q4 2022 Consensus | Delta | Deviation | Q4 2021 | y/y growth |
| :----------------------- | :------------- | :---------------- | :---- | :-------- | :------ | :--------- |
| Product sales            | 48,092         | 47,268            | 824   | 2%        | 38,333  | 25%        |
| Growth in CER            | 17.6%          | 16.4%             |       | 1.2%      | 17.7%   |            |
| * -of which*             |                |                   |       |           |         |            |
| Tresiba                  | 2,247          | 2,573             | -326  | -13%      | 2,731   | -18%       |
| Levemir                  | 959            | 1,016             | -57   | -6%       | 1,273   | -25%       |
| Victoza                  | 3,323          | 2,931             | 392   | 13%       | 3,833   | -13%       |
| Ozempic                  | 16,973         | 17,742            | -769  | -4%       | 10,716  | 58%        |
| Rybelsus                 | 4,053          | 3,215             | 838   | 26%       | 1,823   | 122%       |
| Total Diabetes care      | 37,751         | 37,691            | 60    | 0%        | 31,161  | 21%        |
| Saxenda                  | 3,042          | 3,055             | -13   | 0%        | 1,659   | N/A        |
| Wegovy                   | 2,446          | 1,496             | 950   | 64%       | 800     | 206%       |
| Total Obesity            | 5,488          | 4,552             | 936   | 21%       | 2,459   | 123%       |
| Rare Disease             | 4,853          | 5,025             | -172  | -3%       | 4,713   | 3%         |
| Gross profit             | 39,830         | 39,622            | 208   | 1%        | 32,092  | 24%        |
| Gross margin             | 82.8%          | 83.8%             |       | -1%       | 83.7%   |            |
| EBIT                     | 17,087         | 18,251            | -1,164| -6%       | 13,634  | 25%        |
| EBIT growth in CER       | 17.1%          | 19.9%             |       | -2.8%     | 21.4%   |            |
| EBIT margin              | 35.5%          | 38.6%             |       | -3.1%     | 35.6%   |            |
| Net Income               | 13,592         | 13,266            | 326   | 2%        | 10,892  | 25%        |
| EPS                      | 6.03           | 5.87              | 0.16  | 3%        | 4.77    | 26%        |

Source: Handelsbanken Capital Markets

2

Handelsbanken Capital Markets
```
```markdown
Evaluation Warning: The version can be used only for evaluation purpose...
Results Comment, Novo Nordisk, February 6, 2023
Table 2: Revisions (DKKm)

|                 | 2023e  | 2024e  | 2025e  | 2023e  | 2024e  | 2025e  | 2023   | 2024   | 2025   | 2023 | 2024 | 2025e |
|-----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|------|------|-------|
|                 |        | New    |        |        | Old    |        |        |        | Delta  |      | Diff |       |
| Product sales   | 199,753| 226,936| 257,572| 197,555| 218,445| 241,016| 2,198  | 8,491  | 16,556 | 1%   | 4%   | 7%    |
| Growth in CER   | 14.9%  | 13.6%  | 13.5%  | 11.3%  | 10.6%  | 10.3%  |        |        |        |      |      |       |
| -of which       |        |        |        |        |        |        |        |        |        |      |      |       |
| Tresiba         | 9,376  | 9,631  | 9,942  | 9,492  | 9,919  | 10,320  | -117   | -288   | -378   | -1%  | -3%  | -4%   |
| Levemir         | 3,816  | 3,351  | 3,015  | 3,975  | 3,554  | 3,236  | -159   | -203   | -221   | -4%  | -6%  | -7%   |
| Victoza         | 9,385  | 7.671  | 6,492  | 8,830  | 6,976  | 5,756  | 556    | 695    | 736    | 6%   | 10%  | 13%   |
| Ozempic         | 74,784 | 88,327 | 99,179 | 73.457 | 83,344 | 89,511 | 1,326  | 4,983  | 9,668  | 2%   | 6%   | 11%   |
| Rybelsus        | 17,440 | 25,453 | 34,828 | 14,885 | 20,178 | 26,094 | 2,555  | 5,275  | 8,735  | 17%  | 26%  | 33%   |
| Total Diabetes care | 154,269| 173,787| 193,412| 151,520| 164,557| 175,922| 2,750  | 9,229  | 17,491 | 2%   | 6%   | 10%   |
| Saxenda         | 9,344  | 7,403  | 2,549  | 9,422  | 7,446  | 2,559  | -77    | -43    | -9     | -1%  | -1%  | 0%    |
| Wegovy          | 15,825 | 25,307 | 40,029 | 16,188 | 25,875 | 40,811 | -363   | -568   | -783   | -2%  | -2%  | -2%   |
| Total Obesity   | 25,169 | 32,710 | 42,578 | 25,609 | 33,321 | 43,370 | -440   | -611   | -792   | -2%  | -2%  | -2%   |
| Total Rare Disease | 20,315| 20,384| 20,453| 20,426| 20,511| 20,595| -111| -127| -142| -1%| -1%| -1%|
| Gross profit   | 169,707| 193,290| 220,411| 168,010| 186,235| 206,624| 1,697 | 7,055 | 13,787 | 1%   | 4%   | 7%    |
| Gross margin   | 85.0%  | 85.2%  | 85.6%  | 85.0%  | 85.3%  | 85.7%  |        |        |        |      |      |       |
| R&D costs        | 29,271| 34,574| 39,585| 26,738| 30,160| 33,249| 2,533| 4,413| 6.336| 9%| 15%| 19%|
| Selling expsenses | 53,285| 60,531| 67,117| 53,195| 58,301| 62,779| 90| 2,230| 4,338| 0%| 4%| 7%|
| EBIT            | 83,528  | 94,371  | 109,743 | 84,139  | 93,744  | 106,498 | -612   | 627    | 3,245  | -1%  | 1%   | 3%    |
| EBIT growth in CER | 14.3%  | 13.0%  | 16.3%  | 11.3%  | 11.4%  | 13.6%  |        |        |        |      |      |       |
| EBIT margin       | 41.8%  | 41.6%  | 42.6%  | 42.6%  | 42.9%  | 44.2%  |        |        |        |      |      |       |
| Net Income      | 68,141  | 74,420  | 86,610  | 65,990  | 73,923  | 84,036  | 2,151   | 497    | 2,573  | 3%   | 1%   | 3%    |
| Source: Handelsbanken Capital Markets |         |         |         |         |         |         |        |        |        |      |      |       |
Table 3: HCM vs consensus (DKKm)

|                 | 2023e  | 2024e  | 2025e  | 2023e  | 2024e  | 2025e  | 2023   | 2024   | 2025   | 2023  | 2024   | 2025  |
|-----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|--------|-------|
|                 |        |  HCM   |        |        | Consensus   |        |        |  Delta|        |      | Diff    |        |
| Product sales   | 199,753| 226,936| 257,572| 201,610| 225,033| 249,800| -1,857| 1,903| 7,773| -0.9%| 0.8%| 3.1%|
| Growth in CER   | 14.90%| 13.61%| 13.50%| 15.0%| 11.6%| 11.0%|     |        |        |      |      |       |
| -of which       |        |        |        |        |        |        |        |        |        |      |      |       |
| Tresiba         | 9,376| 9,631| 9,942| 9,806| 10,145| 10.458| -430| -514| -515| -4.4%| -5.1%| -4.9%|
| Levemir         | 3,816| 3,351| 3,015| 4,022| 3,688| 3,419| -206| -338| -404| -5.1%| -9.2%| -11.8%|
| Victoza         | 9,385| 7.671| 6,492| 8,885| 6,609| 5,166| 500| 1,062| 1,326| 5.6%| 16.1%| 25.7%|
| Ozempic         | 74,784| 88,327| 99,179| 76,659| 87,280| 95,424| -1,875| 1,047| 3,755| -2.4%| 1.2%| 3.9%|
| Rybelsus        | 17,440| 25,453| 34,828| 15,902| 21,262| 26,587| 1,538| 4,191| 8,242| 9.7%| 19.7%| 31.0%|
| Total Diabetes care | 154,269| 173,787| 193,412| 156,077| 170,191| 183,654| -1,808| 3,596| 9,759| -1.2%| 2.1%| 5.3%|
| Saxenda         | 9,344| 7,403| 2,549| 8,636| 5,850| 3,980| 708| 1,554| -1,431| 8.2%| 26.6%| -35.9%|
| Wegovy          | 15,825| 25,307| 40,029| 16,190| 27,321| 37,757| -365| -2,014| 2,272| -2.3%| -7.4%| 6.0%|
| Total Obesity   | 25,169| 32,710| 42,578| 24,826| 33,554| 43,630| 343| -844| -1,052| 1.4%| -2.5%| -2.4%|
| Total Rare Disease | 20,315| 20,384| 20,453| 20,694| 20,968| 21,431| -379| -584| -978| -1.8%| -2.8%| -4.6%|
| Gross profit   | 169,707| 193,290| 220,411| 169,790| 189,957| 211,238| -83| 3,333| 9,173| 0.0%| 1.8%| 4.3%|
| Gross margin   | 85.0%| 85.2%| 85.6%| 84.2%| 84.4%| 84.6%|     |        |        |      |      |       |
| R&D costs        | 29,271| 34,574| 39,585| 26,504| 29,953| 33,708| 2,767| 4,621| 5,877| 10.4%| 15.4%| 17.4%|
| Selling expsenses | 53,285| 60,531| 67,117| 51,851| 57,151| 62,644| 1,434| 3,380| 4,473| 2.8%| 5.9%| 7.1%|
| EBIT            | 83,528| 94,371| 109,743| 87,032| 98,019| 109,661| -3,505| -3,648| 82| -4.0%| -3.7%| 0.1%|
| EBIT growth in CER | 14.3%| 13.0%| 16.3%| 15.2%| 12.6%| 11.9%|     |        |        |      |      |       |
| EBIT margin       | 41.8%| 41.6%| 42.6%| 43.2%| 43.5%| 43.9%|     |        |        |      |      |       |
| Net Income      | 68,141| 74,420| 86,610| 68,200| 77.556| 86,925| -60| -3,136| -316| -0.1%| -4.0%| -0.4%|
| EPS      | 30.35| 33.62| 39.76| 30.42| 35.07| 39.88| -0.07| -1.44| -0.12| -0.2%| -4.1%| -0.3%|
| Source: Handelsbanken Capital Markets, Company compiled consensus|      |        |        |        |        |        |     |        |        |      |      |       |

Handelsbanken Capital Markets
3
```
```markdown
Evaluation Warning : The version can be used only for evaluation purpose...
Results Comment, Novo Nordisk, February 6, 2023

Figure 1: Weekly US Wegovy prescriptions per dose
60000
50000
40000
30000
20000
10000
0
27/01/2023 13/01/2023 30/12/2022 16/12/2022 02/12/2022 18/11/2022 04/11/2022

■0.25MG/0.5 ■0.5MG/5ML ■1.7MG/0.75 ■1MG/0.5ML ■2.4MG/0.75
Source: Handelsbanken Capital Markets, Bloomberg

Table 4: Peer group comparison
06 February 2023
| Core | P/E | CAGR | PEG | EV/Sales | EV/EBIT | EV/EBITDA |
| --- | --- | --- | --- | --- | --- | --- |
|  | 2023e | 2024e | 2025e | 3YR | 3YR | 2023e | 2024e | 2025e | 2023e | 2024e | 2025e | 2023e | 2024e | 2025e |
| ABBVIE INC | 12.6 | 13.0 | 12.0 | -3.7 | -3.4 | 5.8 | 5.8 | 5.6 | 11.9 | 11.8 | 10.7 | 10.5 | 10.3 | 10.0 |
| ASTRAZENECA PLC | 17.4 | 14.6 | 13.2 | 13.4 | 1.3 | 4.8 | 4.4 | 4.1 | 15.9 | 12.6 | 11.0 | 13.7 | 11.2 | 9.6 |
| BRISTOL-MYERS SQUIBB CO | 9.3 | 9.1 | 8.8 | 3.5 | 2.7 | 4.0 | 3.9 | 3.8 | 9.0 | 8.4 | 7.8 | 7.3 | 6.9 | 6.6 |
| ELILILLY & CO | 39.6 | 28.6 | 21.5 | 27.1 | 1.5 | 11.0 | 9.2 | 7.7 | 37.3 | 26.4 | 19.7 | 32.0 | 23.3 | 17.4 |
| GSK PLC | 10.0 | 9.4 | 8.5 | 9.1 | 1.1 | 2.6 | 2.4 | 2.3 | 9.5 | 8.5 | 7.6 | 8.2 | 7.4 | 6.7 |
| JOHNSON & JOHNSON | 15.8 | 15.2 | 14.4 | 4.5 | 3.5 | 4.4 | 4.3 | 4.2 | 14.0 | 13.2 | 12.6 | 12.5 | 11.8 | 11.1 |
| MERCK & CO. INC. | 14.5 | 12.0 | 10.8 | 8.8 | 1.6 | 4.8 | 4.6 | 4.3 | 12.5 | 10.1 | 8.9 | 11.1 | 9.1 | 8.1 |
| NOVARTIS AG-REG | 13.2 | 12.2 | 11.5 | 7.5 | 1.8 | 4.1 | 3.9 | 3.8 | 13.0 | 11.9 | 11.2 | 11.5 | 10.5 | 9.8 |
| PFIZER INC | 11.3 | 11.2 | 11.0 | -15.0 | -0.8 | 3.5 | 3.5 | 3.5 | 10.5 | 9.1 | 8.8 | 9.1 | 8.3 | 8.1 |
| ROCHE HOLDING AG-GENUSSCHEIN | 14.1 | 13.0 | 12.0 | 4.7 | 3.0 | 4.1 | 3.9 | 3.7 | 11.4 | 10.2 | 9.4 | 9.9 | 8.9 | 8.2 |
| SANOFI | 10.2 | 9.4 | 8.5 | 6.7 | 1.5 | 2.5 | 2.4 | 2.3 | 8.7 | 7.6 | 6.6 | 7.4 | 6.6 | 5.7 |
| Large cap pharma average | 15.3 | 13.4 | 12.0 | 6.0 | 1.3 | 4.7 | 4.4 | 4.1 | 13.9 | 11.8 | 10.4 | 12.1 | 10.4 | 9.2 |
| Large cap pharma median | 13.2 | 12.2 | 11.5 | 6.7 | 1.5 | 4.1 | 3.9 | 3.8 | 11.9 | 10.2 | 9.4 | 10.5 | 9.1 | 8.2 |
| NOVO NORDISK A/S-B | 31.2 | 27.3 | 24.0 | 18.1 | 1.7 | 10.8 | 9.6 | 8.7 | 25.4 | 22.3 | 19.7 | 23.6 | 20.6 | 18.4 |
| Premium (+)/Discount (-) to average | 104% | 103% | 99% | 199% | 37% | 131% | 119% | 111% | 82% | 89% | 90% | 95% | 98% | 100% |
| Premium (+)/Discount (-) to median | 136% | 123% | 109% | 169% | 14% | 163% | 144% | 126% | 113% | 118% | 109% | 125% | 127% | 124% |
Source: Handelsbanken Capital Markets, Bloomberg

Handelsbanken Capital Markets
```
```markdown
Evaluation Warning: The version can be used only for evaluation purpose...
Results Comment, Novo Nordisk, February 6, 2023

Figure 2: Novo NTM P/E
12m fwd P/E vs 10y ave

40x
35x
30x
25x
20x
15x
10x
5x
0x
17/01/2013 17/01/2016 17/01/2019 17/01/2022

-Novo P/E NTM -10y avg.

Figure 3: Novo NTM P/E vs peers
Novo 12m fwd P/E vs sector
2.5
2.0
1.5
1.0
0.5
0.0
17/01/2013 17/01/2017 17/01/2021

-Novo P/E NTM - Premium / Discount 10y avg

Source: Handelsbanken Capital Markets, Bloomberg
Source: Handelsbanken Capital Markets, Bloomberg

Handelsbanken Capital Markets
5
```
```markdown
Evaluation Warning : The version can be used only for evaluation purpose...
Results Comment, Novo Nordisk, February 6, 2023

P&L out come

| DKKm              | Actual | Growth % Y-o-y | Qo-q  | Deviation % HCM | Cons |
|-------------------|--------|----------------|-------|-----------------|------|
| Sales             | 48,092 | 25.5           | 5.5   | 2.5             | 1.8  |
| Gross profit      | 39,830 | 24.1           | 3.8   | 0.02            | n.m  |
| Gross margin (%)  | 82.8   |                |       |                 |      |
| EBIT adj          | 17,087 | 25.3           | -15.3 | 1.0             | -6.6 |
| margin (%)        | 35.5   |                |       |                 |      |
| EBT               | 16,316 | 24.4           | -9.5  | 3.8             | 1.1  |
| Netincome         | 13,592 | 24.8           | -5.6  | 9.1             | 4.0  |
| EPS reported (DKK) | 5.9    | 26.9           | -5.9  | 8.5             | 3.6  |
| EPS adj (DKK)     | 5.9    | 26.9           | -5.9  | 8.5             | 0.36 |

Source: Company data, Handelsbanken Capital Markets and FactSet

Trend analysis

| %               | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23e |
|-----------------|-------|-------|-------|-------|-------|-------|
| Sales y-o-y     | 19.3  | 24.3  | 24.9  | 27.9  | 25.5  | 13.8  |
| EBIT adj y-o-y  | 22.0  | 27.8  | 24.4  | 32.4  | 25.3  | 9.8   |
| EBIT adj margin | 35.6  | 45.6  | 44.6  | 44.3  | 35.5  | 44.0  |
| EPS adj (DKK)   | 4.62  | 6.2   | 5.8   | 6.2   | 5.9   | 7.6   |
| EPS adj y-o-y   | 18.1  | 14.5  | 11.8  | 20.9  | 26.9  | 24.0  |

Source: Company data, Handelsbanken Capital Markets

Business areas - quarterly data

| DKKm               | Q4 21  | Q1 22  | Q2 22  | Q3 22  | Q4 22  | Q1 23e |
|--------------------|--------|--------|--------|--------|--------|--------|
| Sales              |        |        |        |        |        |        |
| Insulin            | 13,973 | 14,962 | 12,343 | 12,961 | 12,686 | 0.0    |
| GLP-1              | 16,372 | 17,420 | 19,231 | 22,368 | 24,352 | 0.0    |
| Obesity            | 2,459  | 3,402  | 3,643  | 4,331  | 5,488  | 0.0    |
| Haemophilia        | 2.490  | 3.077  | 2,863  | 2,885  | 2.881  | 0.0    |
| Other rare disease | 4.713  | 5,363  | 5,218  | 5,108  | 4,853  | 0.0    |
| Total              | 38,333 | 42,031 | 41,265 | 45,566 | 48,092 | 47,846 |

| Y-o-y sales growth (%) |       |        |        |        |        |        |
|------------------------|-------|--------|--------|--------|--------|--------|
| Insulin                | 2.5   | 0.65   | -6.2   | -7.5   | -9.2   | n.m    |
| GLP-1                  | 39.0  | 54.2   | 59.2   | 61.5   | 48.7   | n.m    |
| Obesity                | 77.5  | 119    | 82.9   | 80.6   | 123    | n.m    |
| Haemophilia            | 16.4  | 14.9   | 5.1    | 24.0   | 15.7   | n.m    |
| Other rare disease     | 7.8   | 7.8    | 4.2    | 13.3   | 3.0    | n.m    |
| Total                  | 19.3  | 24.3   | 24.9   | 27.9   | 25.5   | 13.8   |

Source: Handelsbanken Capital Markets

Handelsbanken Capital Markets
```
```markdown
Evaluation Warning: The version can be used only for evaluation purpose...
Results Comment, Novo Nordisk, February 6, 2023

Estimate changes

| DKKm        | Q1 23e | chg (%) | HCM 2023e | chg (%) | HCM 2024e | chg (%) |
| ----------- | ------ | ------- | --------- | ------- | --------- | ------- |
| Sales       | 47,846 | 6       | 199.753   | 1       | 226,936   | 4       |
| EBITA adj   | 21,429 | 8       | 85,127     | -1      | 95,970     | 0       |
| EBIT adj    | 21.029 | 9       | 83,528     | -1      | 94,371     | 1       |
| margin (%)  | 44.0   | 3       | 41.8       | -2      | 41.6       | -3      |
| EBT         | 21,929 | 17      | 85,928     | 3       | 93,846     | 1       |
| Net income  | 17,390 | 17      | 68,141     | 3       | 74,420     | 1       |
| EPS (DKK)   | 7.6    | 17      | 30.3       | 3       | 33.6       | 1       |
| EPS adj (DKK) | 7.6    | 17      | 30.3       | 3       | 33.6       | 1       |

Source: Handelsbanken Capital Markets

HCM vs. consensus

| DKKbn        | Q1 23e | diff (%) | Cons 2023e | diff (%) | Cons 2024e | diff (%) |
| ----------- | ------ | -------- | ---------- | -------- | ---------- | -------- |
| Sales       | 47.5   | 1        | 201.3      | -1       | 228.0      | 0       |
| EBIT adj   | 19.6   | 7        | 86.5      | -3       | 97.1      | -3       |
| margin (%) | 41.3   | 3        | 42.9      | -1       | 42.6      | -1       |
| EBT         | 18.7   | 17       | 87.0      | -1       | 96.1      | -2       |
| Net income  | 16.0   | 9        | 68.8      | -1       | 76.7      | -3       |
| EPS (DKK)   | 7.1    | 7        | 31.1      | -2       | 35.6      | -5       |
| EPS adj (DKK) | 7.2    | 6        | 30.7      | -1       | 35.1      | -4       |

Source: Handelsbanken Capital Markets and FactSet

ESG analysis, environmental

![ESG Environmental Chart](attachment:image.png)

Source: Company data, Handelsbanken Capital Markets

ESG analysis, social

![ESG Social Chart](attachment:image.png)

Source: Company data, Handelsbanken Capital Markets

Risks
* Low innovation would translate to increased competition
* Increased pricing pressure from healthcare reforms
* Biosimilar competition to insulin and biopharmaceuticals
* Success of public initiatives to curb obesity epidemic
* Pipeline failures

Source: Handelsbanken Capital Markets

Handelsbanken Capital Markets 7
```
```markdown
Evaluation Warning: The version can be used only for evaluation purpose...
Results Comment, Novo Nordisk, February 6, 2023

Valuation charts

Current vs. high/low/me dian, 10 years *
P/E x
P/BV EV/Sales EV/EBITDA EV/EBIT
26.2 12.2 26.3 29.0
-26.2 -12.2 -26.2 -28.8

14.8 6.8 14.9 16.1

11.3 5.1 10.7 11.2

EV/EBITDA x
EV/EBIT x
30 30

16 17 20 21 22 2
-P/E adjusted

M
10 10
14 15 16 17 19 20 21 22 23 15 16 17 18 19 20 21 22 23
-EV/EBITDA -EV/EBIT

P/BV x and ROE %
30
22
M
EV/sales x and EBIT margin %
14
72
12
54
10
10
14 15 16 17 18 19 20 21 22
-P/BV ROE (RHS)
14 15 16 17 18 19 20 21 22 23
-EV/Sales EBIT margin (RHS)

FCFE yield %
Dividend (ordinary) and 10-year bond yield %
M
15 17 18 19 20
- FCFE
21 22
23
15 16
18 19 20 21 22 23
-Div Yield-Bond Yield

Source: Handelsbanken Capital Markets and company fundamentals
Note: The current value is the figure on the left-hand side and the median value is depicted by the arrow on the right-hand side.

Handelsbanken Capital Markets
```
```markdown
Evaluation Warning: The version can be used only for evaluation purpose...
Results Comment, Novo Nordisk, February 6, 2023

Momentum

Revenues 2023 estimate revisions

Revenues 2024 estimate revisions

DKK
213k
205k
197k
189k
181k
173k
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb
-Revenues -Cons.

EPS 2023 estimate revisions
DKK
237k
227k
217k
207k
197k
187k
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb
-Revenues -Cons.

EPS 2024 estimate revisions

DKK
33
DKK
38
31
29
27
36
34
32
30
25
28
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb
-Adj. EPS-Cons.
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb
-Adj. EPS-Cons.

Source: Handelsbanken Capital Markets and FactSet

Valuation da ta

|DKK K|2011|2012|2013|2014|2015|2016|2017|2018|2019|2020|2021|2022|2023e|2024e|2025e|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|Share price year-end/current|132|183|199|260|400|255|335|298|387|427|735|938|958|958|958|
|Share price high|141|196|220|286|415|407|340|355|394|468|774|946|976|-|
|Share price low|101|130|170|198|261|218|226|265|296|332|418|604|897|-|
|Market cap (m)|370,039|501,020|530,894|681,681|1,024,197|640,533|823,489|720,278|920,169|1,002,628|1,697,850|2,138,640|2,130,990|2,099,039|2,063,894|
|Net debt(m)|-16444|-17877|-19,398|-15,040|-20,660|-21,745|-19,888|-15,844|-12,495|-5,074|7.567|9770|-1,975|2,093|-268.0|
|MV associates (m)|39.0|39.0|39.0|-|582.0|525.0|527.0|327.0|327.0|327.0|
|EV (m)|353,556|483,104|511,458|666,641|1,003,537|618,788|803,601|704,434|907,874|996,972|1,704,892|2,137,336|2,128,688|2,100,805|2,063,299|

|PE reported (x)|21.8|23.5|21.1|25.9|29.4|17.0|21.7|18.7|23.6|23.7|35.4|38.4|31.6|28.5|24.1|
|PE adj (x)|21.8|23.5|21.1|24.8|29.4|17.0|21.7|18.7|23.6|23.7|35.4|38.4|31.6|28.5|24.1|
|P/CEPS (x)|18.8|20.9|19.2|23.5|27.5|15.9|20.3|17.7|21.9|21.8|31.8|34.6|28.1|25.4|21.5|
|P/BV (X)|9.9|125|12.4|16.9|21.8|14.1|16.5|13.9|16.0|15.8|31.1|25.7|21.9|19.3|16.2|
|ROE adj(%)|46.0|552|60.5|96.0|79.9|81.9|80.2|75.3|71.2|69.7|71.2|72.0|75.3|71.9|73.1|
|Pre-tax ROIC (%)|102|137|137|141|192|194|183|143|131|108|88.3|96.0|95.6|92.7|93.3|

|EVsales (x)|53|6.2|6.1|7.5|9.3|5.5|7.2|6.3|7.4|7.9|12.1|12.1|10.7|9.3|8.0|
|EV/EBITDA (x)|14.1|15.0|15.1|17.5|19.3|12.2|15.6|14.1|15.9|16.7|26.4|26.0|23.5|20.6|17.4|
|EV/EBIT (X)|158|164|16.2|18.7|20.3|12.8|164|14.9|17.3|18.4|29.1|28.6|25.5|22.3|18.8|
|EBIT adj margin (%)|33.7|37.8|37.7|40.0|45.9|43.3|43.8|42.2|43.0|42.6|41.7|42.3|41.8|41.6|42.6|

|FCF adj yield (%)|4.9|3.7|4.5|3.7|3.2|5.3|4.4|4.3|3.4|4.6|2.9|3.1|2.6|2.8|3.4|
|Tot div yield (%)|1.9|1.7|1.5|1.5|1.4|2.3|2.3|2.7|2.2|2.1|1.4|1.3|1.6|1.8|2.1|
|Payout ratio (%)|410|40.5|40.1|40.0|39.8|39.7|51.0|51.2|51.0|50.5|50.1|50.7|50.3|50.3|50.4|

Source: Handelsbanken Capital Markets

Handelsbanken Capital Markets
```
Evaluation Warning: The version can be used only for evaluation purpose...

Results Comment, Novo Nordisk, February 6, 2023

Peer group v aluation

| CCY | Price (Sh. curr.) | Mcap (EURbn) | EV/S(x) | E/EBIT(x) | P/Eadj. (x) | ROIC ind. GW (%) | EBIT-margin (%) |
| ----------- | ----------- | ----------- | ----------- | ----------- | ----------- | ----------- | ----------- |
|   |   |   | 2023e | 2024e | 2025e | 2023e | 2024e | 2025e | 2023e | 2024e | 2025e | 2023e | 2024e | 2025e |
| Novo Nordisk | DKK | 958 | 286 | 10.7 | 9.3 | 8.0 | 25.5 | 22.3 | 18.8 | 31.6 | 28.5 | 24.1 | 95.6 | 92.7 | 93.3 | 41.6 | 41.6 | 42.6 |
| AstraZeneca | SEK | 1,342 | 183 | 4.5 | 4.0 | 3.5 | 14.5 | 12.0 | 10.2 | 18.3 | 15.6 | 13.6 | 25.3 | 32.0 | 39.2 | 20.1 | 23.2 | 25.5 |
| Bayer | EUR | 56.7 | 55.7 | 1.7 | 1.6 | 1.5 | 9.2 | 8.6 | 6.7 | 7.2 | 6.8 | 6.5 | 13.2 | 13.5 | 16.5 | 18.3 | 18.4 | 22.5 |
| Bristol-Myers Squibb | USD | 74.5 | 146 | 3.8 | 3.5 | 3.2 | 9.2 | 8.5 | 7.7 | 9.3 | 9.0 | 8.7 | 36.6 | 42.3 | 45.7 | 41.1 | 40.5 | 41.6 |
| Eli Lilly | USD | 339 | 308 | 11.3 | 9.4 | 7.9 | 38.8 | 28.0 | 20.6 | 40.1 | 29.6 | 21.7 | 41.0 | 54.8 | 67.9 | 29.2 | 33.6 | 38.1 |
| GlaxoSmithKline | GBP | 14.4 | 65.7 | 2.5 | 2.2 | 2.1 | 8.5 | 7.6 | 7.0 | 9.8 | 9.2 | 8.3 | 25.3 | 24.6 | 28.0 | 29.4 | 29.5 | 30.5 |
| Johnson & Johnson | USD | 165 | 396 | 4.4 | 4.2 | 4.1 | 13.8 | 13.1 | 12.6 | 15.7 | 15.1 | 14.5 | 40.3 | 39.7 | 37.9 | 31.8 | 32.2 | 32.3 |
| Lundbeck | DKK | 26.0 | 3.5 | 1.2 | 0.9 | 0.7 | 4.9 | 3.4 | 2.7 | 7.6 | 6.2 | 6.0 | 24.7 | 32.1 | 36.2 | 16.5 | 19.7 | 20.1 |
| Merck | USD | 103 | 240 | 4.7 | 4.2 | 3.9 | 12.7 | 10.0 | 8.9 | 14.9 | 11.9 | 10.6 | 34.7 | 41.7 | 44.5 | 36.9 | 42.1 | 43.5 |
| Novartis | USD | 86.2 | 191 | 4.1 | 3.9 | 3.7 | 12.5 | 11.5 | 11.0 | 13.2 | 12.2 | 11.5 | 25.9 | 28.5 | 30.7 | 32.8 | 33.5 | 34.5 |
| Roche Holding | CHF | 282 | 233 | 3.8 | 3.5 | 3.3 | 11.1 | 9.9 | 9.2 | 14.3 | 13.1 | 12.0 | 44.8 | 46.3 | 44.7 | 34.3 | 35.0 | 35.6 |
| Pfizer | USD | 44.1 | 228 | 3.7 | 3.5 | 3.6 | 11.8 | 10.1 | 10.5 | 12.8 | 11.2 | 10.9 | 19.0 | 20.8 | 20.0 | 31.4 | 34.5 | 34.5 |
| Sanofi | EUR | 85.1 | 107 | 2.4 | 2.2 | 2.0 | 8.3 | 7.5 | 6.5 | 10.1 | 9.3 | 8.4 | 17.8 | 19.3 | 28.8 | 29.4 | 29.8 | 30.9 |
| Average |  |  |  | 4.5 | 4.0 | 3.7 | 13.9 | 11.7 | 10.2 | 15.8 | 13.7 | 12.1 | 34.1 | 37.4 | 40.3 |  |  |  |
| Median |  |  |  | 3.8 | 3.5 | 3.5 | 11.8 | 10.0 | 9.2 | 13.2 | 11.9 | 10.9 | 25.9 | 32.1 | 37.9 |  |  |  |
| Average excl. Novo Nordisk |  |  |  | 4.0 | 3.6 | 3.3 | 12.9 | 10.8 | 9.5 | 14.4 | 12.4 | 11.1 | 28.9 | 32.8 | 35.9 |  |  |  |
| Median excl. Novo Nordisk |  |  |  | 3.8 | 3.5 | 3.4 | 11.5 | 10.0 | 9.0 | 13.0 | 11.5 | 10.7 | 25.6 | 32.1 | 37.0 |  |  |  |

Source: Handelsbanken Capital Markets and FactSet

DCF model assumptions

| DKKbn | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e | 2032e | 2037e | 2042e |
| ----------- | ----------- | ----------- | ----------- | ----------- | ----------- | ----------- | ----------- | ----------- | ----------- |
| Sales | 177.0 | 199.8 | 226.9 | 257.6 | 283.2 | 308.0 | 446.9 | 625.6 | 847.5 |
| EBITDA - Reported | 82.1 | 90.6 | 102.2 | 118.4 | 129.6 | 144.3 | 219.4 | 260.2 | 288.9 |
| EBITA2 - Reported (=EBITA bef gw amort) (use: IS) | 74.8 | 83.5 | 94.4 | 109.7 | 120.2 | 134.2 | 201.1 | 234.6 | 254.3 |
| Sales CAGR (%) | 25.7 | 12.9 | 13.6 | 13.5 | 9.9 | 8.8 | 7.7 | 7.0 | 6.3 |
| EBITDA growth (%) | 27.0 | 10.3 | 12.8 | 15.9 | 9.5 | 11.3 | 8.7 | 3.5 | 2.1 |
| EBITA growth (%) | 27.6 | 11.7 | 13.0 | 16.3 | 9.6 | 11.6 | 8.4 | 3.1 | 1.6 |
| EBITDA margin (%) | 46.4 | 45.4 | 45.0 | 46.0 | 45.8 | 46.8 | 49.1 | 41.6 | 34.1 |
| EBITA margin (%) | 42.3 | 41.8 | 41.6 | 42.6 | 42.5 | 43.6 | 45.0 | 37.5 | 30.0 |
| Capex/sales (%) | 6.9 | 12.5 | 13.0 | 12.0 | 10.0 | 8.0 | 4.5 | 4.5 | 4.5 |
| Capex/depreciation (x) | 1.9 | 3.5 | 3.8 | 3.6 | 3.0 | 2.4 | 1.1 | 1.1 | 1.1 |
| Networking cap/sales (%) | -21.2 | -21.2 | -21.2 | -21.2 | -21.2 | -21.2 | 15.0 | 13.0 | 11.0 |

WACC assumptions

| WACC assumptions (%) | Calculation of DCF (DKKm) | DCF checkpoints |
| ----------- | ----------- | ----------- |
| Risk-free interest rate | 2.0 | NPV FCFF | 2,683,813 | DCF checkpoints (%) |
| Equity market risk premium | 4.5 | ND inc off-BS & Hybrids | -977 | 5y hist sales growth | 9.6 |
| Equitybeta (x) | 0.96 | Market value Preferred stock | 0.0 | 5y exp sales growth | 11.7 |
| Implicitassetbeta (x) | 0.96 | Market value Associates | 327 | Sustainable growth | 2.0 |
| Cost of equity | 6.3 | Market value Minorities | 0.0 | Sust EBITDA margin | 34.1 |
| Pre-tax cost of debt | 2.0 | Surplus values | 0.0 | Sust EBITA margin | 30.0 |
| Equity weight | 100 | Other adjustments | 0.0 | Sust after-tax ROIC | 81.2 |
| WACC | 6.3 | DCF value | 2,685,117 | Terminal value/DCF | 50.0 |
|   |   | DCF value/share (DKK) | 1,207 | Implicit equity weight | 100 |
|   |   |   | Share price potential to DCF value | 26.0 |

Source: Handelsbanken Capital Markets

10
Handelsbanken Capital Markets

